Literature DB >> 25818678

Soluble c5b-9 as a biomarker for complement activation in atypical hemolytic uremic syndrome.

Fengxiao Bu1, Nicole C Meyer1, Yuzhou Zhang1, Nicolo Ghiringhelli Borsa1, Christie Thomas1, Carla Nester1, Richard J H Smith2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25818678     DOI： 10.1053/j.ajkd.2015.02.326

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  17 in total

Review 1.  The Evolving Landscape for Complement Therapeutics in Rheumatic and Autoimmune Diseases.

Authors:  Joshua M Thurman; Ashley Frazer-Abel; V Michael Holers
Journal:  Arthritis Rheumatol       Date:  2017-10-17       Impact factor: 10.995

2.  Monitoring Complement Activation: The New Conundrum in Thrombotic Microangiopathies.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Clin J Am Soc Nephrol       Date:  2019-11-06       Impact factor: 8.237

3.  Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series.

Authors:  Rupali S Avasare; Pietro A Canetta; Andrew S Bomback; Maddalena Marasa; Yasar Caliskan; Yasemin Ozluk; Yifu Li; Ali G Gharavi; Gerald B Appel
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-11       Impact factor: 8.237

Review 4.  Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

Authors:  Fadi Fakhouri; Véronique Frémeaux-Bacchi
Journal:  Nat Rev Nephrol       Date:  2021-05-05       Impact factor: 28.314

5.  HUS with mutations in CFH and STEC infection treated with eculizumab in a 4-year-old girl.

Authors:  Carla Galvez; Paola Krall; Alejandro Rojas; Jun Oh; Francisco Cano
Journal:  Pediatr Nephrol       Date:  2022-08-15       Impact factor: 3.651

Review 6.  All Things Complement.

Authors:  Joshua M Thurman; Carla M Nester
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

7.  Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.

Authors:  F Corvillo; M Bravo García-Morato; P Nozal; S Garrido; A Tortajada; S Rodríguez de Córdoba; M López-Trascasa
Journal:  Clin Exp Immunol       Date:  2016-01-22       Impact factor: 4.330

Review 8.  Tissue-targeted complement therapeutics.

Authors:  Stephen Tomlinson; Joshua M Thurman
Journal:  Mol Immunol       Date:  2018-07-07       Impact factor: 4.407

9.  Mutation of complement factor B causing massive fluid-phase dysregulation of the alternative complement pathway can result in atypical hemolytic uremic syndrome.

Authors:  Yuzhou Zhang; Robin A Kremsdorf; C John Sperati; Kammi J Henriksen; Mari Mori; Renee X Goodfellow; Gabriella R Pitcher; Cindy L Benson; Nicolo Ghiringhelli Borsa; Ronald P Taylor; Carla M Nester; Richard J H Smith
Journal:  Kidney Int       Date:  2020-06-12       Impact factor: 10.612

10.  Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2.

Authors:  Caroline Diorio; Sarah E Henrickson; Laura A Vella; Kevin O McNerney; Julie Chase; Chakkapong Burudpakdee; Jessica H Lee; Cristina Jasen; Fran Balamuth; David M Barrett; Brenda L Banwell; Kathrin M Bernt; Allison M Blatz; Kathleen Chiotos; Brian T Fisher; Julie C Fitzgerald; Jeffrey S Gerber; Kandace Gollomp; Christopher Gray; Stephan A Grupp; Rebecca M Harris; Todd J Kilbaugh; Audrey R Odom John; Michele Lambert; Emily J Liebling; Michele E Paessler; Whitney Petrosa; Charles Phillips; Anne F Reilly; Neil D Romberg; Alix Seif; Deborah A Sesok-Pizzini; Kathleen E Sullivan; Julie Vardaro; Edward M Behrens; David T Teachey; Hamid Bassiri
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.